Finally, because NK cells from healthy donors display similar phenotypic and fitness characteristics to NK cells from AML patients and ALL patients, whatever the stage of their disease, we forecast that expression of HLA-E is likely to protect ΔTRACCARΔB2MHLAE from NK cells in the majority of AML and ALL patients. The gene discussed is HLA-E; the disease is acute myeloid leukemia.